News Center

• Nov. 15

  2022

  CSPC's Three Latest Research Findings of Class 1 New Drug Selected for World Stroke Congress (WSC) (I)

  The 14th World Stroke Congress (WSC) was held in Singapore from October 26-29, 2022, by the World Stroke Organization (WSO). The three latest research findings of CSPC's class I new drug, Butylphthalide (NBP), for treating acute ischemic stroke, were selected for this Congress.

• Nov. 15

  2022

  A Subsidiary of CSPC Passes EcoVadis Social Responsibility Certification

  Recently, EcoVadis, a global corporate social responsibility (CSR) evaluation authority, completed the social responsibility audit and certification of Hebei Huarong Pharmaceutical Co., Ltd. (Huarong Pharmaceutical), a subsidiary of CSPC.

• Oct. 28

  2022

  ANTIBODY-DRUG CONJUGATE “SYS6002” OBTAINS CLINICAL TRIAL APPROVAL

  The antibody-drug conjugate “SYS6002" developed by the Group has obtained clinical trial approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

• Oct. 25

  2022

  “TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS” OBTAINS DRUG REGISTRATION APPROVAL

  “Tofacitinib Citrate Extended-Release Tablets (11mg)” developed by CSPC has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China.

• Oct. 25

  2022

  Latest Results of Duomeisu in the Treatment of Sarcoma Released

  A study about Duomeisu was successfully published in the journal of Clinical Cancer Research (IF: 13.801, JCR Division: Medical Division 1).

• Oct. 12

  2022

  EXCLUSIVE LICENSE AGREEMENT FOR BATOCLIMAB (HBM9161)

  CSPC entered into an exclusive license agreement with “Shanghai HBM”,pursuant to which CSPC obtained an exclusive license from Shanghai HBM to develop, manufacture and commercialize batoclimab (HBM9161) in Greater China.